<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603431</url>
  </required_header>
  <id_info>
    <org_study_id>MRG110-01-001</org_study_id>
    <nct_id>NCT03603431</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of MRG-110 Following Local Intradermal Injection After Skin Excisional Wound Creation in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>miRagen Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>miRagen Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MRG-110 is intended to promote the growth of new blood vessels by inhibiting a molecule
      called miR-92a. MRG-110 is being studied to determine if it can accelerate healing of wounds
      by improving blood flow into the wound area. The primary objective of this study is to
      investigate the safety and tolerability of MRG-110 when injected into the skin at the site of
      a small skin wound in normal healthy volunteers. Another objective is to study the
      pharmacokinetics of MRG-110 (the movement of a drug into, through and out of the body).
      Participants in the clinical trial will receive either a single dose or multiple doses of
      MRG-110 and/or placebo. Blood samples, urine samples and skin biopsies will be collected to
      measure how MRG-110 is processed by the body, and how the body responds when exposed to
      MRG-110.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Actual">March 13, 2019</completion_date>
  <primary_completion_date type="Actual">March 13, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.</measure>
    <time_frame>Up to Day 55</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration vs. time curve (AUC) of MRG-110 following single and repeat doses.</measure>
    <time_frame>Up to Day 45</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of MRG-110 following single and repeat doses</measure>
    <time_frame>Up to Day 45</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Area of granulation tissue formation</measure>
    <time_frame>Day 11 or Day 18</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Histological markers of angiogenesis (such as CD31, ERG, ITGA5)</measure>
    <time_frame>Day 11 or Day 18</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Wound perfusion measured by laser speckle imaging</measure>
    <time_frame>Up to Day 45</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of wounds closed over time</measure>
    <time_frame>Up to Day 55</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose - MRG-110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intradermal injection of placebo at four wound sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose - MRG-110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intradermal injection of placebo at four wound sites</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRG-110</intervention_name>
    <description>Single ascending doses of MRG-110</description>
    <arm_group_label>Single Ascending Dose - MRG-110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single doses of placebo</description>
    <arm_group_label>Single Ascending Dose - MRG-110</arm_group_label>
    <arm_group_label>Single Ascending Dose - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRG-110</intervention_name>
    <description>Multiple ascending doses of MRG-110</description>
    <arm_group_label>Multiple Ascending Dose - MRG-110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple doses of Placebo</description>
    <arm_group_label>Multiple Ascending Dose - MRG-110</arm_group_label>
    <arm_group_label>Multiple Ascending Dose - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Normal healthy volunteers.

          -  Females must be of non-childbearing potential.

          -  If engaged in sexual relations with a female of child-bearing potential, males must be
             surgically sterile or must be willing to use a highly effective method of
             contraception throughout their study participation and for at least 6 months after the
             last dose of study drug.

          -  Must have 2 regions on lower back/upper buttocks that are free of striae, scars,
             tattoos, or other skin pathologies.

          -  Must have no conditions that could increase risk of abnormal or delayed healing.

        Key Exclusion Criteria:

          -  Clinically significant abnormalities in medical history or physical examination.

          -  Clinically significant abnormalities in laboratory tests at screening.

          -  History of cutaneous disorder.

          -  Hemangioma, history of hemangioblastoma, or other known vascular disorder.

          -  Positive for bloodborne pathogen (hepatitis B, hepatitis C, HIV).

          -  Use of an investigational drug or device within 28 days prior to Day 1, or use of an
             investigational biological or oligonucleotide drug within 90 days of Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Escolar, MD</last_name>
    <role>Study Director</role>
    <affiliation>miRagen Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion, Inc.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <keyword>MicroRNAs</keyword>
  <keyword>Angiogenesis Inducing Agents</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

